Peter Klemm

View Point Medical, Inc. engages in the provision of medical device and technology focuses on surgical outcomes using novel tissue markers that enable lesion localization in cancer care. It offers SignalMark platform. The company was founded by William Blair and Jeffrey Port and is headquartered in Carlsbad, CA.

GeneOhm Sciences, Inc. develops molecular diagnostic products. It offers methicillin-resistant staphylococcus aureus (MRSA) Assay an in vitro diagnostic test for the direct detection of MRSA from a nasal specimen. The company was founded on 2001 and is headquartered in Franklin Lakes, NJ.

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.

Applied Proteomics, Inc. develops protein biomarkers for the healthcare and drug development sectors. It specializes in blood-based multiplex protein tests to help physicians, direct patients towards current standard-of-care patient management. The company was founded by David B. Agus and W. Daniel Hillis in May 2007 and is headquartered in San Diego, CA.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.